期刊文献+

他汀类调脂药和ACEI对急性冠脉综合征患者血清中炎性指标的影响 被引量:1

The effects of HMGCoA agents and ACE inhibitor on the serum inflammatory markers in patients with acute coronary syndrome
暂未订购
导出
摘要 目的 观察他汀类调脂药和血管紧张素转化酶抑制剂 (angiotensin convertingenzymeinhibitor ,ACEI)对急性冠脉综合征患者血清中炎性指标的影响。方法 选取急性冠脉综合征 (acutecoronarysyndrome ,ACS)患者 6 0例 ,随机分为调脂治疗组和ACEI+调脂治疗组 ,在 4个月后进行随访。采用酶联免疫法测定上述病例和对照血清中一些炎性指标的水平 ,并进行统计学分析。结果 血清中某些炎性因子在ACS组中高于对照组 ,并在随访时明显降低。 4个月后所有炎性指标在调脂治疗组和ACEI+调脂治疗组之间均无显著性差异。结论 血清中某些炎性因子的水平可以作为诊断和预测ACS发生的敏感指标 ,并反应病情的稳定情况 ; Objective To explore the effects of HMGCoA agents and ACE inhibitor on serum inflammatory markers in patients with acute coronary syndrome (ACS). Methods The 60 patients with ACS were randomly divided into two groups, one treated with lipid lowered by HMGCoA agents and the other treated with HMGCoA agents added with ACE inhibitor. After 4 months, serum levels of some inflammatory markers were measured by means of ELISA. Results Serum levels of certain inflammatory markers were significantly higher in the ACS group than in the control group and became significantly lower 4 months later in the follow-up group. There were no differences in all the inflammatory markers between the two groups receiving different therapies 4 months later. Conclusion Serum levels of some inflammatory markers may have certain diagnostic value for ACS and may reflect the stability of the disease. HMGCoA agents seem to have no effect on inflammatory responses in a short period.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2004年第2期135-137,共3页 Journal of Xi’an Jiaotong University(Medical Sciences)
关键词 他汀类调脂药 ACEI 急性冠脉综合征 血清 炎性指标 药物治疗 血管紧张素转化酶抑制剂 acute coronary syndrome inflammation ACE inhibitor follow-up
  • 相关文献

参考文献2

二级参考文献8

共引文献42

同被引文献12

  • 1李红辉,刘恩波,谢群,李家富,何涛.罗格列酮对2型糖尿病合并高血压患者血压的作用[J].心血管康复医学杂志,2005,14(4):347-349. 被引量:7
  • 2胡彪,林坚鹏.罗格列酮对2型糖尿病合并不稳定型心绞痛患者血脂及hs-CRP水平的影响[J].国际医药卫生导报,2005,11(20):18-20. 被引量:1
  • 3洪燕.心绞痛患者血肿瘤坏死因子及C反应蛋白浓度的变化[J].心血管康复医学杂志,2007,16(1):34-35. 被引量:8
  • 4Braunwald E,Antman EM,Beasley JW,et al.ACC /AHA guidelines for the management of patients with unstable angina and non-ST-segement elevation myocardial infarction.A report of American college of cardiology/American heart association task force or parctice guidelines[J ].J Am Coll Cariol,2000,36 (3):970.
  • 5Haffiner SM,Gonzalez C,Miettinen H,et al.A prospective analysis of the HOMA model.The Mexico city diadetes study[ J].Dia Care,1996,19 (10):1138-1141.
  • 6vanderWal AC,Piek JJ,deBoer OJ,et al.Recent onset activation of the plaque immune response in coronary lesions underlying acute coronary syndromes[J].Heart,1998,80 (1):14-18.
  • 7Pearson TA,Mensah GA,Alexander RW,et al.Markers of inflammation and cardiovascular disease,application to clinical and public health practice:A statement for healthcare professionals from the centers for disease control and prevention and the American heart association[J].Circulation,2003,107:499-502.
  • 8Mohanty P,Aljada A,Ghanim H,et al.Evidence for a potent anti-inflammatory effect of rosiglitazone[J].J Clin Endocrinol Metab,2004,89 (6):272.
  • 9Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J].N Engl J Med,2007,356 (24):2457-2471.
  • 10Libby P,Ridker PM,Maseri A.Inflammation and atherosclerosis[J].Circulation,2002,105 (9):1135.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部